IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
IceCure 醫療報告了ICE3乳腺癌冷凍消融試驗的最終結果；數據已提交給美國食品藥品管理局申請上市許可以治療早期乳腺癌
- Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons
- President-Elect of the ASBrS, Dr. Michael Berry, presents data and states "cryoablation is ready for prime time"
- Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy
- Available reimbursement code for facility expense expected to enhance usage upon receiving marketing authorization
- Minimally-invasive ProSense cryoablation offers highly favorable healthcare economics
- 理查德·芬博士在極具影響力的美國乳腺外科學會（“ASBR”）年會上發表的數據榮獲由乳腺外科醫生投票選出的科學影響獎
- ASBR當選主席邁克爾·貝里博士提供了數據並表示 “冷凍消融已爲黃金時段做好準備”
- 公司尋求輔助激素療法治療早期T1浸潤性乳腺癌女性的適應症
- 獲得上市許可後預計將提高使用率的設施費用的可用補償代碼
- 微創 ProSense 冷凍消融可提供非常有利的醫療保健經濟性
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。